Gsk Plc-spon Adr. Share Price (NYSE: GSK)

$39.67

▲

0.23

(0.58%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Gsk Plc-spon Adr. Stock chart to analyse performance

Gsk Plc-spon Adr. stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$39.22
Today's High:$39.67
$39.67
1.13%
Downside
Day's Volatility :1.13%
Upside
0.0%
52 Weeks Low:$31.72
52 Weeks High:$44.26
$39.67
20.05%
Downside
52 Weeks Volatility :28.34%
Upside
10.37%

Gsk Plc-spon Adr. Stock Returns

Period	Gsk Plc-spon Adr.	Russel 2000	Index (Russel 2000)
3 Months	-4.78%	0.0%	0.0%
6 Months	4.53%	0.0%	0.0%
1 Year	-8.68%	0.0%	0.0%
3 Years	24.55%	-3.0%	-3.0%

Gsk Plc-spon Adr. Key Stats

Check Gsk Plc-spon Adr. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$39.44
Open	$39.29
Today's High	$39.67
Today's Low	$39.22
Market Capitalization	$79.9B
Today's Volume	$3.6M
52 Week High	$44.26
52 Week Low	$31.715
Revenue TTM	$31.6B
EBITDA	$9.3B
Earnings Per Share (EPS)	$2.23
PE Ratio	17.79
Dividend Yield	4.15%
Profit Margin	10.82%
Quarterly Earnings Growth YOY	0.23%
Return On Equity TTM	28.33%

Stock Returns calculator for Gsk Plc-spon Adr. Stock including INR - Dollar returns

The Gsk Plc-spon Adr. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Gsk Plc-spon Adr. investment value today

Current value as on today

₹96,605

Returns

₹3,395

(-3.39%)

Returns from Gsk Plc-spon Adr. Stock

₹8,679 (-8.68%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Gsk Plc-spon Adr. Stock

10%

Period: Aug 1, 2025 to Aug 31, 2025. Change in 30 Days versus previous period

Search interest for Gsk Plc-spon Adr. Stock from India on INDmoney has increased by 10% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Gsk Plc-spon Adr.

Name
Holdings %
Name
Holdings %
Dodge & Cox
3.90%
FMR Inc
2.98%
Fisher Asset Management, LLC
1.55%
PRIMECAP Management Company
1.37%
JTC Employer Solutions Trustee Ltd
0.76%
T. Rowe Price Associates, Inc.
0.40%

Analyst Recommendation on Gsk Plc-spon Adr. Stock

Rating

Trend

Buy

60%Buy

30%Hold

9%Sell

Based on 33 Wall street analysts offering stock ratings for Gsk Plc-spon Adr.(by analysts ranked 0 to 5 stars)

Gsk Plc-spon Adr. Share Price Target

What analysts predicted

Downside of 1.62%

Target:

$39.03

Current:

$39.67

Gsk Plc-spon Adr. share price target is $39.03, a slight Downside of 1.62% compared to current price of $39.67 as per analysts' prediction.

Gsk Plc-spon Adr. Stock Insights

Price Movement
In the last 3 months, GSK stock has moved down by -3.3%
Increasing Revenue
GSK Plc's revenue has shown positive growth over the last two quarters. It increased from $7.51 billion to $7.98 billion, representing an average growth of 5.9% per quarter.
Decreasing Net Profit
GSK Plc's stock performance shows a declining trend in net profit over the last two quarters, with profits decreasing from $1.62 billion to $1.44 billion. This represents an average decrease of 11.2% per quarter.
GSK vs ABBV (1 yr)
In the last 1 year, Abbvie Inc has given 7.2% return, outperforming this stock by 16.9%
GSK vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 52.0% return, outperforming this stock by 26.8%
Price to Sales
GSK Plc's price-to-sales ratio is 2.6, meaning investors are willing to pay $2.6 for every $1 of sales the company makes. In comparison, Abbvie Inc's higher price-to-sales ratio of 6.4 indicates that investors are willing to pay $6.4 for every $1 of sales, suggesting that they perceive Abbvie's sales as more valuable relative to GSK's.

Gsk Plc-spon Adr. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$44.2B	↑ 9.52%
Net Income	$6.1B	↑ 28.21%
Net Profit Margin	13.76%	↑ 2.01%

	FY20	Y/Y Change
Revenue	$45.8B	↑ 1.02%
Net Income	$7.7B	↑ 23.77%
Net Profit Margin	16.86%	↑ 3.1%

	FY21	Y/Y Change
Revenue	$45.4B	↑ 0.04%
Net Income	$5.8B	↓ 23.73%
Net Profit Margin	12.85%	↓ 4.01%

	FY22	Y/Y Change
Revenue	$35.7B	↓ 14.04%
Net Income	$6.0B	↑ 12.22%
Net Profit Margin	16.78%	↑ 3.93%

	FY23	Y/Y Change
Revenue	$38.4B	↑ 3.42%
Net Income	$6.2B	↑ 0.14%
Net Profit Margin	16.25%	↓ 0.53%

	FY24	Y/Y Change
Revenue	$39.7B	↑ 3.46%
Net Income	$3.3B	↓ 47.75%
Net Profit Margin	8.21%	↓ 8.04%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$9.4B	↓ 8.56%
Net Income	$1.3B	↑ 198.86%
Net Profit Margin	14.21%	↑ 9.86%

	Q2 FY24	Q/Q Change
Revenue	$10.0B	↑ 7.08%
Net Income	$1.5B	↑ 12.14%
Net Profit Margin	14.88%	↑ 0.67%

	Q3 FY24	Q/Q Change
Revenue	$10.6B	↑ 1.62%
Net Income	$-76.6M	↓ 104.94%
Net Profit Margin	-0.72%	↓ 15.6%

	Q4 FY24	Q/Q Change
Revenue	$10.3B	↑ 1.31%
Net Income	$523.4M	↓ 813.79%
Net Profit Margin	5.1%	↑ 5.82%

	Q1 FY25	Q/Q Change
Revenue	$9.7B	↓ 7.4%
Net Income	$2.1B	↑ 292.27%
Net Profit Margin	21.61%	↑ 16.51%

	Q2 FY25	Q/Q Change
Revenue	$8.0B	↑ 6.25%
Net Income	$1.4B	↓ 11.15%
Net Profit Margin	18.07%	↓ 3.54%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$28.7B	↑ 6.37%

	FY20	Y/Y Change
Profit	$30.1B	↑ 2.3%

	FY21	Y/Y Change
Profit	$29.9B	↑ 0.52%

	FY22	Y/Y Change
Profit	$24.1B	↓ 12.18%

	FY23	Y/Y Change
Profit	$27.6B	↑ 10.08%

	FY24	Y/Y Change
Profit	$28.2B	↑ 2.6%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$6.9B	↓ 5.04%

	Q2 FY24	Q/Q Change
Profit	$7.4B	↑ 6.95%

	Q3 FY24	Q/Q Change
Profit	$7.4B	↓ 3.24%

	Q4 FY24	Q/Q Change
Profit	$7.0B	↓ 1.02%

	Q1 FY25	Q/Q Change
Profit	$7.2B	↑ 0.38%

	Q2 FY25	Q/Q Change
Profit	$5.8B	↑ 4.34%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$10.5B	↓ 4.76%
Investing Cash Flow	$-7.0B	↑ 244.75%
Financing Cash Flow	$-2.4B	↓ 71.2%

	FY20	Y/Y Change
Operating Cash Flow	$11.3B	↑ 5.25%
Investing Cash Flow	$2.9B	↓ 140.36%
Financing Cash Flow	$-13.6B	↑ 450.65%

	FY21	Y/Y Change
Operating Cash Flow	$10.6B	↓ 5.79%
Investing Cash Flow	$-2.4B	↓ 182.23%
Financing Cash Flow	$-10.1B	↓ 25.1%

	FY22	Y/Y Change
Operating Cash Flow	$9.0B	↓ 6.9%
Investing Cash Flow	$-10.7B	↑ 393.64%
Financing Cash Flow	$1.0B	↓ 110.84%

	FY23	Y/Y Change
Operating Cash Flow	$8.6B	↓ 8.58%
Investing Cash Flow	$-2.0B	↓ 81.82%
Financing Cash Flow	$-7.1B	↓ 785.42%

	FY24	Y/Y Change
Operating Cash Flow	$8.3B	↓ 3.16%
Investing Cash Flow	$-1.6B	↓ 22.95%
Financing Cash Flow	$-6.0B	↓ 16.22%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$1.2B	↓ 68.39%
Investing Cash Flow	$-255.5M	↓ 197.1%
Financing Cash Flow	$-1.3B	↓ 70.08%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$1.1B	↓ 6.07%
Investing Cash Flow	$929.1M	↓ 463.68%
Financing Cash Flow	$-1.7B	↑ 32.86%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$2.8B	↑ 144.22%
Investing Cash Flow	$-965.4M	↓ 200.0%
Financing Cash Flow	$-1.6B	↓ 5.63%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$2.9B	↑ 8.12%
Investing Cash Flow	$-1.4B	↑ 53.08%
Financing Cash Flow	$-1.1B	↓ 32.1%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$1.5B	↓ 50.84%
Investing Cash Flow	$-1.5B	↑ 2.23%
Financing Cash Flow	$1.1B	↓ 201.9%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$2.1B	↑ 83.06%
Investing Cash Flow	$-625.0M	↓ 45.37%
Financing Cash Flow	$-2.4B	↓ 376.46%

Gsk Plc-spon Adr. Technicals Summary

Sell

Neutral

Buy

Gsk Plc-spon Adr. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Gsk Plc-spon Adr. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Gsk Plc-spon Adr.	5.28%	4.53%	-8.68%	24.55%	-20.46%
Eli Lilly And Company	-4.74%	-21.2%	-23.41%	143.12%	389.86%
Johnson & Johnson	3.58%	5.91%	5.99%	8.87%	15.17%
Merck & Co. Inc.	5.33%	-9.69%	-27.84%	-2.45%	-3.23%
Novo Nordisk A/s	15.67%	-36.82%	-58.56%	10.45%	70.52%
Abbvie Inc	6.7%	-0.51%	6.43%	54.39%	123.95%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Gsk Plc-spon Adr.	17.79	17.79	0.4	4.13	0.28	0.07	0.04	3.66
Eli Lilly And Company	47.85	47.85	1.06	22.83	0.86	0.17	0.01	20.38
Johnson & Johnson	18.97	18.97	1.07	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	12.96	12.96	0.83	8.93	0.35	0.13	0.04	19.57
Novo Nordisk A/s	14.51	14.51	1.67	24.83	0.79	0.22	0.03	37.82
Abbvie Inc	100.19	100.19	0.44	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Gsk Plc-spon Adr.	Buy	$79.9B	-20.46%	17.79	10.82%
Eli Lilly And Company	Buy	$656.7B	389.86%	47.85	25.91%
Johnson & Johnson	Buy	$426.7B	15.17%	18.97	25.0%
Merck & Co. Inc.	Buy	$210.1B	-3.23%	12.96	25.79%
Novo Nordisk A/s	Buy	$248.7B	70.52%	14.51	35.61%
Abbvie Inc	Buy	$371.7B	123.95%	100.19	6.45%

Gsk Plc-spon Adr. Dividend announcements

Gsk Plc-spon Adr. Dividends June, 2025
In the quarter ending June,2025. Gsk Plc-spon Adr. has declared dividend of $0.43

About Gsk Plc-spon Adr.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.

Organization	Gsk Plc-spon Adr.
Employees	68629
CEO	Ms. Emma Natasha Walmsley
Industry	Health Technology

Key Management of Gsk Plc-spon Adr.

Name	Title
Ms. Emma Natasha Walmsley	CEO & Director
Ms. Julie Belita Brown A.C.A.	CFO & Executive Director
Dr. Jesse L. Goodman M.D., M.P.H.	Scientific & Medical Expert
Ms. Shobie Ramakrishnan	Chief Digital & Technology Officer
Mr. Tony Wood	Chief Scientific Officer and Head of R&D
Mr. Constantin Fest	Senior VP & Head of Investor Relations
Mr. James Ford	Senior VP & Group General Counsel of Legal & Compliance
Ms. Sally Jackson	Senior VP of Global Communications & CEO Office
Mr. David Simon Redfern BSc (Hons), CA	President of Corporate Development
Ms. Diana Conrad	Chief People Officer

Important FAQs about investing in GSK Stock from India :

What is Gsk Plc-spon Adr. share price today?

Gsk Plc-spon Adr. share price today is $39.67 as on August 30, 2025 at 1:29 am IST at the close of the market. Gsk Plc-spon Adr. share today touched a day high of $39.67 and a low of $39.22.

What is the 52 week high and 52 week low for Gsk Plc-spon Adr. share?

Gsk Plc-spon Adr. share touched a 52 week high of $44.26 and a 52 week low of $31.72. Gsk Plc-spon Adr. stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $39.67, lower by 10.37% versus the 52 week high.

How to invest in Gsk Plc-spon Adr. Stock (GSK) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Gsk Plc-spon Adr. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gsk Plc-spon Adr. Shares that will get you 0.0378 shares as per Gsk Plc-spon Adr. share price of $39.67 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Gsk Plc-spon Adr. Stock (GSK) from India?

Indian investors can start investing in Gsk Plc-spon Adr. (GSK) shares with as little as ₹88.286 or $1 (as of September 01, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Gsk Plc-spon Adr. stock (as per the Rupee-Dollar exchange rate as on September 01, 2025). Based on Gsk Plc-spon Adr. share’s latest price of $39.67 as on August 30, 2025 at 1:29 am IST, you will get 0.2521 shares of Gsk Plc-spon Adr.. Learn more about fractional shares .

What are the returns that Gsk Plc-spon Adr. has given to Indian investors in the last 5 years?

Gsk Plc-spon Adr. stock has given -20.46% share price returns and 20.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?